ACRS Stock Overview
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Aclaris Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$16.82 |
| 52 Week High | US$18.96 |
| 52 Week Low | US$9.84 |
| Beta | 0.58 |
| 1 Month Change | 8.59% |
| 3 Month Change | 9.43% |
| 1 Year Change | 62.20% |
| 3 Year Change | 1,256.45% |
| 5 Year Change | -19.75% |
| Change since IPO | 52.22% |
Recent News & Updates
Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Dec 21
Recent updates
Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Dec 21Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Aug 26Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth
May 28We're Not Very Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate
Dec 14Is Aclaris Therapeutics (NASDAQ:ACRS) Using Too Much Debt?
Aug 25Shareholders Will Probably Not Have Any Issues With Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) CEO Compensation
May 28Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Path To Profitability
Feb 28How Much Of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Do Insiders Own?
Dec 18
Is Aclaris Therapeutics (NASDAQ:ACRS) Weighed On By Its Debt Load?
Nov 27Shareholder Returns
| ACRS | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 1.0% | -0.5% | 2.3% |
| 1Y | 62.2% | 5.4% | -9.7% |
Return vs Industry: ACRS exceeded the US Pharmaceuticals industry which returned 7.9% over the past year.
Return vs Market: ACRS exceeded the US Market which returned -8.5% over the past year.
Price Volatility
| ACRS volatility | |
|---|---|
| ACRS Average Weekly Movement | 7.5% |
| Pharmaceuticals Industry Average Movement | 11.1% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: ACRS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: ACRS's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 75 | Doug Manion | https://www.aclaristx.com |
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases.
Aclaris Therapeutics, Inc. Fundamentals Summary
| ACRS fundamental statistics | |
|---|---|
| Market Cap | US$1.12b |
| Earnings (TTM) | -US$82.08m |
| Revenue (TTM) | US$23.50m |
47.7x
P/S Ratio-13.7x
P/E RatioIs ACRS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACRS income statement (TTM) | |
|---|---|
| Revenue | US$23.50m |
| Cost of Revenue | US$82.44m |
| Gross Profit | -US$58.94m |
| Other Expenses | US$23.14m |
| Earnings | -US$82.08m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.23 |
| Gross Margin | -250.80% |
| Net Profit Margin | -349.26% |
| Debt/Equity Ratio | 0% |
How did ACRS perform over the long term?
See historical performance and comparison